MVM Partners, a venture capital firm, and Gilde Healthcare, a specialized healthcare investor, led a $104m Series D round in Nalu Medical, a medical device company that develops and commercializes neuromodulation systems, with participation from Pura Vida, Aperture Venture Partners, Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital. “This additional funding underscores the potential of Nalu’s miniaturized technology and will allow us to accelerate the already strong adoption of our system. We welcome the addition of new top-tier investors and appreciate the continued support of our current investors, who share our mission of commercializing innovative and minimally invasive solutions that make meaningful differences to people suffering from chronic pain,” Earl Fender, Nalu President and CEO.